VIM and glioblastoma: In this regard, in a mouse model of GBM, the VEGFA blockade was observed and in GBM patients treated with bevacizumab, a pro-invasive phenotype with increased cell migration/invasion, associated with a mesenchymal phenotype with high vimentin levels was reported [61].